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Introduction
Lyn kinase is a Src-family tyrosine kinase expressed by
hematopoietic and non-hematopoietic cell types. It
functions as an activactor and an inhibitor of signaling
pathways. Phosphorylation of a tyrosine residue at position
508 keeps the molecule in an inactive form. Lynup/up mice
have a gain-of-function mutation generated at the tyrosine
position 508 (Y508F) and present with severe anemia,
autoimmune glomerulonephritis and positive ANA. Using
whole exome sequencing (WES), we identified a pediatric
patient with a nonsense de novo mutation in lyn kinase
presenting with an early-onset autoinflammatory
phenotype.
Objectives
To describe the successful characterization by WES of a
patient with a de novo mutation in LYN, a gene not
previously associated with human disease.
Methods
Genomic DNA was extracted from total blood of the
patient and his parents and WES was performed using
human exome capture Agilent V4 enrichment kit and
Illumina HiSeq2000 platform.
Results
A 3 year-old Caucasian male born at 31 weeks’ gesta-
tion presented with hydrops fetalis, requiring intra-
utero blood transfusion. Post partum he developed
hepatosplenomegaly, purpuric skin rash, periorbital
erythema and testicular swelling. Laboratory exams
showed increased C-reactive protein (CRP) anemia,
severe thrombocytopenia and increased liver enzymes.
At 9 months of age a splenectomy was performed for
refractory thrombocytopenia. Post splenectomy, he
developed leukocytosis, thrombocytosis and anemia
persisted. A liver biopsy showed periportal lymphocytic
infiltrate and vanishing bile duct disease. He had vascu-
litis on a skin biopsy and circulating autoantibodies
(positive ANA, anti-Sm, anti-SSA, anti-phospholipids
and anti-mitochondrial antibodies). Despite some
improvement after initiation of prednisone and IVIG
infusions, prednisone doses could not be weaned. We
identified a de novo mutation in a candidate gene
(LYN) by WES. The mutation was confirmed as de
novo by Sanger sequencing. The change from cytosine
to guanine (c.1524C>G) leads to a premature stop-codon
at the tyrosine position (Y508*) with loss of the phos-
phorylation site. B lymphocytes showed a constitutive
phosphorylation of lyn and B cell phenotyping showed a
significantly diminished frequency of immature B cell
populations in peripheral blood and in bone marrow.
B cell activation was reduced upon IgM stimulation in
comparison with healthy controls. The genetic defect
identified in this patient led us to initiate treatment with
a tyrosine kinase inhibitor (dasatinib). After 6 months of
treatment, clinical improvement was observed with lower
frequency of disease flares, resolution of anemia,
improvement of leukocytosis, thrombocytosis and liver
enzymes. A decrease of prednisone dose to physiologic
levels and discontinuation of IVIG infusions were also
achieved.
1National Institute of Arthritis Musculoskeletal and Skin diseases (NIAMS),
Bethesda, USA
Full list of author information is available at the end of the article
De Jesus et al. Pediatric Rheumatology 2014, 12(Suppl 1):O25
http://www.ped-rheum.com/content/12/S1/O25
© 2014 De Jesus et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Conclusion
A lyn kinase nonsense mutation was detected in a patient
with a severe early-onset autoinflammatory phenotype.
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